How Long Do Allergy Shots Take to Start Working? Early Signs of Response

IgG4 is an immunoglobulin antibody subclass produced by B cells in response to repeated allergen exposure during immunotherapy. Unlike IgE — the antibody that triggers allergic reactions — IgG4 acts as a blocking antibody, competitively binding allergen before it can cross-link IgE on mast cells and basophils. When IgG4 occupies allergen-binding sites, it prevents the cascade that would otherwise release histamine, leukotrienes, and other inflammatory mediators responsible for allergy symptoms. IgG4 levels begin rising within the first few months of SCIT and reach 10- to 100-fold increases from baseline by 12-18 months of maintenance (Nikolov et al., Antibodies 2021). Importantly, the functional IgE-blocking activity of IgG4 — not just the absolute concentration — correlates most closely with clinical improvement (Shamji et al., Allergy 2012). Patients who show no IgG4 rise by 12 months may be non-responders requiring dose adjustment.

Allergists use several tools to monitor early treatment response. Skin prick test (SPT) reactivity — the size of the wheal produced by an allergen challenge — decreases measurably between 6-12 months of SCIT and provides an objective, in-office measure of desensitization. Nasal provocation tests assess how much allergen is needed to trigger symptoms; this threshold increases at 6 months and continues improving through 24 months (Scadding et al., JACI 2010). The symptom-medication score is a composite endpoint combining symptom severity ratings with rescue medication use that clinical trials use to quantify patient benefit — statistically significant improvement appears at 6-8 months of maintenance. Serum IgG4 levels can be measured by specialized labs and serve as the best biomarker for monitoring immunologic response. Patient-reported outcome measures, including quality-of-life questionnaires (RQLQ) and daily symptom diaries, provide the subjective complement to these objective tests.

A temporary worsening of symptoms, or heightened sensitivity around injection visits, is possible during early build-up and does not necessarily indicate treatment failure. The allergen being injected is the same substance causing your allergy, so some increased reactivity in the hours following an injection is expected — this is why the 30-minute observation period exists. Local injection-site reactions (redness, swelling, itching at the injection site) occur in 26-86% of patients and are considered a normal part of treatment, not a sign that shots are making allergies worse (Tankersley et al., JACI 2000). Systemic symptom worsening during your allergen's peak season in the first treated year can also occur, because your immune system is still in the early stages of developing tolerance. If you experience what feels like a meaningful overall deterioration in allergy control after several months of treatment, discuss it with your allergist — it may indicate a dose that needs adjustment.

Skin prick test wheal size reduction is a useful but imperfect marker of immunologic response. The absence of SPT change at 12 months is not necessarily a sign of treatment failure, because SPT reactivity and clinical benefit do not always correlate directly — some patients experience meaningful clinical improvement while SPT remains elevated. Conversely, SPT normalization can occur without proportional symptom improvement. The more diagnostically informative question is whether IgG4 levels have risen and whether the functional IgE-blocking activity is detectable. If both SPT reactivity and symptom-medication scores show no change after 12 months of maintenance at adequate doses, and allergen selection has been confirmed as clinically appropriate, that combination warrants a frank reassessment conversation. The AAAAI Practice Parameter recommends evaluating whether dose adequacy, allergen relevance, and environmental allergen exposure levels may be contributing before concluding treatment is ineffective.

Yes — the speed of early response varies between individuals, and several factors predict faster versus slower initial response. Monosensitized patients — those treated for a single primary allergen — tend to show earlier and more pronounced IgG4 responses than polysensitized patients with multiple allergen groups in their treatment vials. Younger patients and those with shorter disease duration at treatment initiation show faster immune adaptation. Higher baseline allergen-specific IgE levels (above approximately 17.5 kU/L for dust mites) were associated with better early response in Lee et al. (2018). Patients starting SCIT outside their pollen season — allowing unimpeded dose escalation during build-up — may reach the maintenance dose faster and perceive earlier first-season benefit. Interestingly, predictive analytics from clinical cohort studies show that the clinical response at month 4 correlates strongly with 24-month outcomes (r=0.707), and month-12 response predicts 24-month success with an AUC of 0.860 — meaning early responders tend to be strong long-term responders.

Specific blood tests can provide objective evidence of immunologic response, though they are not routinely ordered by all allergists. Allergen-specific IgG4 measurement is the most clinically useful test — a significant rise in IgG4 to your treated allergens by 12-18 months confirms the core immunologic mechanism is active. Allergen-specific IgE levels may transiently rise in the first months of SCIT before ultimately declining — so early IgE elevation is expected and should not be misinterpreted as worsening sensitization. The ratio of sIgG4 to sIgE (Nikolov et al., Antibodies 2021 found this ratio improved in 90% of patients after 3 years of SCIT) provides more clinical signal than either value alone. Basophil activation tests — measuring how easily your basophils release histamine when challenged with allergen — can detect functional desensitization at 3-4 months, even before symptom improvement, but these tests are primarily research tools and may not be available in all clinical settings.